Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Change in Accured Expenses: 2012-2025

Historic Change in Accured Expenses for Agios Pharmaceuticals (AGIO) over the last 13 years, with Sep 2025 value amounting to $1.9 million.

  • Agios Pharmaceuticals' Change in Accured Expenses rose 156.13% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.9 million, marking a year-over-year increase of 38.80%. This contributed to the annual value of $3.7 million for FY2024, which is 71.18% down from last year.
  • According to the latest figures from Q3 2025, Agios Pharmaceuticals' Change in Accured Expenses is $1.9 million, which was down 86.73% from $14.5 million recorded in Q2 2025.
  • In the past 5 years, Agios Pharmaceuticals' Change in Accured Expenses registered a high of $14.5 million during Q2 2025, and its lowest value of -$26.1 million during Q1 2025.
  • In the last 3 years, Agios Pharmaceuticals' Change in Accured Expenses had a median value of $1.9 million in 2025 and averaged $624,273.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first skyrocketed by 1,244.17% in 2022, then crashed by 364.03% in 2024.
  • Over the past 5 years, Agios Pharmaceuticals' Change in Accured Expenses (Quarterly) stood at $2.7 million in 2021, then surged by 90.78% to $5.2 million in 2022, then surged by 143.13% to $12.7 million in 2023, then rose by 6.92% to $13.6 million in 2024, then soared by 156.13% to $1.9 million in 2025.
  • Its Change in Accured Expenses was $1.9 million in Q3 2025, compared to $14.5 million in Q2 2025 and -$26.1 million in Q1 2025.